COMP <GO>
GILD vs UNH // EV/EBITDA & P/E VALUATION
Gilead Sciences Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GILD 7
— UNH 7
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $165.61 (+4.03%) • MKT CAP: $205.35B
valuation
21.0x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 88.57% | -9.77 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 11.47% | +9.53 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 16.4x | +4.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 6.48% | -1.88 | UNH | /fcf-yield <GO> |
| Operating Margin | 34.00% | 4.82% | +29.18 | GILD | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 3.14% | +25.76 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 6.46% | -4.06 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 2.28% | -0.33 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 3.12 | +2.75 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.3 | 59.2 | +5.10 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | GILD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 17.1x | +5.31 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $368.83B | -$163.48B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | UNH REV | GILD GROSS % | UNH GROSS % | GILD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $447.57B | 78.8% | 88.7% | $9.46B | $16.07B |
| FY 2024 | $28.75B | $400.28B | 78.3% | 88.3% | $10.30B | $20.70B |
| FY 2023 | $27.12B | $371.62B | — | 89.6% | $6.79B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
UNH // BETA 0.33